Literature DB >> 18551620

Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment.

Simona Venturoli1, Simone Ambretti, Monica Cricca, Elisa Leo, Silvano Costa, Monica Musiani, Marialuisa Zerbini.   

Abstract

The evidence on genotype-specific risk in women infected with human papillomavirus (HPV) with normal cytology and the importance of the distinction of high-risk (HR)-HPV genotypes in the management of low-grade lesions suggest that the distinction of HR-HPV genotypes has the potential to improve the follow-up of patients treated for high-grade cervical lesions. The aims of this study were to define the persistence of the different HR-HPV in the follow-up of surgical treated women, to detect the changes of genotypes from the pre- to the post-operative status, and to evaluate whether genotype-specific persistence can predict the development of residual or recurrent disease during the follow-up. HR-HPV detection and genotyping was carried out by the Linear Array HPV Genotyping Test on cervical cytological samples from 72 women treated by surgery. The 6-month post-operative HPV status was correlated with the pre-operative HPV genotype and with the residual or recurrent disease within 24 months. It was observed that the residual or recurrent disease in women with persistence of HPV 16 and/or HPV 18 was higher (82.4%) than in women with persistence of at least one HR-HPV type of group 2 (HPV 31, 33, 35, 45, 52, and 58) (66.7%) and at least one type of group 3 (HPV 39, 51, 56, 59, 68, 26, 53, 66, 73, and 82) (14.3%). These data defined HR-HPV groups for the risk of progression of disease and suggested that the identification of persistent infection with different HR-HPV genotypes has the potential to improve the management of these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18551620     DOI: 10.1002/jmv.21198

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

Review 1.  The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.

Authors:  Anne F Rositch; Heidi M Soeters; Tabatha N Offutt-Powell; Bradford S Wheeler; Sylvia M Taylor; Jennifer S Smith
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

Review 2.  Emerging human papillomavirus vaccines.

Authors:  Barbara Ma; Bharat Maraj; Nam Phuong Tran; Jayne Knoff; Alexander Chen; Ronald D Alvarez; Chien-Fu Hung; T-C Wu
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-19       Impact factor: 4.191

3.  Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus.

Authors:  Anna Söderlund-Strand; Joyce Carlson; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

Review 4.  A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients.

Authors:  Stefan Miladinov Kovachev
Journal:  Infect Drug Resist       Date:  2021-06-02       Impact factor: 4.003

5.  Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, Italy.

Authors:  Andrea Piana; Giovanni Sotgiu; Paolo Castiglia; Stefania Pischedda; Clementina Cocuzza; Giampiero Capobianco; Vincenzo Marras; Salvatore Dessole; Elena Muresu
Journal:  BMC Public Health       Date:  2011-10-11       Impact factor: 3.295

6.  HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice.

Authors:  M Origoni; P Cristoforoni; S Costa; L Mariani; P Scirpa; A Lorincz; M Sideri
Journal:  Ecancermedicalscience       Date:  2012-06-18

7.  Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Systematic Review.

Authors:  Fabio Bottari; Anna D Iacobone; Rita Passerini; Eleonora P Preti; Maria T Sandri; Clementina E Cocuzza; Devin S Gary; Jeffrey C Andrews
Journal:  Obstet Gynecol       Date:  2019-09       Impact factor: 7.623

Review 8.  Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma.

Authors:  Silvano Costa; Simona Venturoli; Massimo Origoni; Mario Preti; Luciano Mariani; Paolo Cristoforoni; Maria Teresa Sandri
Journal:  Ecancermedicalscience       Date:  2015-04-29

9.  High HPV-51 prevalence in invasive cervical cancers: results of a pre-immunization survey in North Sardinia, Italy.

Authors:  Andrea Piana; Giovanni Sotgiu; Clementina Cocuzza; Rosario Musumeci; Vincenzo Marras; Stefania Pischedda; Silvia Deidda; Elena Muresu; Paolo Castiglia
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  HPV-Based Screening, Triage, Treatment, and Followup Strategies in the Management of Cervical Intraepithelial Neoplasia.

Authors:  Oscar Peralta-Zaragoza; Jessica Deas; Claudia Gómez-Cerón; Wendy Argelia García-Suastegui; Geny Del Socorro Fierros-Zárate; Nadia Judith Jacobo-Herrera
Journal:  Obstet Gynecol Int       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.